KA
CLVS

Kozak & Associates’s Clovis Oncology, Inc. CLVS Stock Holding History

Kozak & Associates’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-140
Closed – – 357
2022
Q4 		$0 Hold
140
– – ﹤0.01% 346
2022
Q3 		$0 Hold
140
– – ﹤0.01% 390
2022
Q2 		$0 Hold
140
– – ﹤0.01% 400
2022
Q1 		$0 Hold
140
– – ﹤0.01% 385
2021
Q4 		$0 Hold
140
– – ﹤0.01% 393
2021
Q3 		$1K Buy
+140
New +$674 ﹤0.01% 323

Other funds holding CLVS

RMC
Resources Management Corp West Hartford, Connecticut $753M AUM 20.77% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

Kozak & Associates's CLVS Position: Q1 2023 in Review

Kozak & Associates sold out of Clovis Oncology, Inc. (CLVS) in Q1 2023, closing a stake of 140 shares.

Kozak & Associates first reported a position in CLVS in Q3 2021 and held it in 6 quarters. The position peaked at $1K in Q3 2021. 2 funds tracked by Wall St. Rank hold CLVS as of Q1 2023.

  • Kozak & Associates reported no remaining Clovis Oncology, Inc. position as of Q1 2023 after selling out during the quarter.
  • Kozak & Associates sold 140 Clovis Oncology, Inc. shares in Q1 2023.
  • Kozak & Associates first reported a position in Clovis Oncology, Inc. in Q3 2021 and held it in 6 quarters.
  • Kozak & Associates's Clovis Oncology, Inc. position peaked at $1K in Q3 2021.
  • 2 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q1 2023.

Based on Kozak & Associates's 13F filing for Q1 2023, filed 3 Apr 2023.